Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare BBA Agreement Expected To Reach Floor Week of Nov. 15

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Balanced Budget Refinement Act (HR 3075) could reach the floor of the House Nov. 16, and the Senate the next day, following an agreement between congressional conferees and the White House reached late in the evening of Nov. 10.

You may also be interested in...



BBA Medicare legislation

House adopts Rep. Bill Thomas' (R-Calif.) "Medicare Balanced Budget Refinement Act" Nov. 5 in a 388-25 floor vote. HR 3075 was supported by House Commerce Chairman Thomas Bliley (R-Va.). Language is retained that increases reimbursement rates for pap smears from $7.15 to a minimum of $14.60 for conventional and automated pap tests inserted into the legislation by Rep. Jennifer Dunn (R-Wash.). House conferees are expected to be named the week of Nov. 8

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel